All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Efficacy of Camrelizumab with Raltitrexed in the Therapy of Advanced Gastric Cancer on Postoperative Recurrence and Metastasis

Author(s): C. Liu, T. Chen and M. Liu*
Department of Pharmacy, 1Emergency Department, 2Department of Gastrointestinal and Hepatobiliary Surgery, Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technoloy, Wuhan, Hubei Province 430063, China

Correspondence Address:
M. Liu, Department of Gastrointestinal and Hepatobiliary Surgery, Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technoloy, Wuhan, Hubei Province 430063, China, E-mail: 15827187072@163.com


To authenticate the clinical outcome of camrelizumab united with raltitrexed in the therapy of advanced gastric cancer and postoperative recurrent and metastatic gastric cancer. From January 2018 to March 2021, the clinical data of 80 sufferers with advanced gastric cancer and postoperative recurrent and metastatic gastric cancer treated in our hospital were estimated retrospectively. According to the different therapy methods, the sufferers were separated into two subgroups. 42 sufferers in the survey subgroup were treated with camrelizumab monoclonal antibody plus raltitrexed plus routine chemotherapy, and 38 sufferers in the control subgroup were treated with raltitrexed plus routine chemotherapy for 3 consecutive cycles. The short-term efficacy, serum tumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9), adverse reactions and survival were compared among the two subgroups. The objective response rate and disease control rate in the survey subgroup were 54.76 % and 80.95 % respectively, which were notablely boosted than those in the control subgroup (31.58 % and 57.89 %). After therapy, the concentrations of serum carcinoembryonic antigen and carbohydrate antigen 19-9 in the survey subgroup were notablely lessened than those in the control subgroup. There were no IV grade serious adverse reactions and fewer III grade adverse reactions among the two subgroups. There was no notable divergence in the incidence of common adverse reactions such as nausea and vomiting, liver and kidney function damage, myelosuppression, skin rash, anemia and reactive cutaneous capillary endothelial proliferation among the two subgroups. The median progression-free survival in the survey subgroup and the control subgroup was 9.31 mo and 6.57 mo respectively, and the divergence was statistically notable. Camrelizumab united with raltitrexed can improve the short-term and long-term efficacy of advanced gastric cancer and postoperative recurrent and metastatic gastric cancer with high safety and no increase of drug side outcomes.

Full-Text | PDF

 
 
Google scholar citation report
Citations : 61564

Indian Journal of Pharmaceutical Sciences received 61564 citations as per google scholar report